IL175424A0 - 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) - Google Patents

4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Info

Publication number
IL175424A0
IL175424A0 IL175424A IL17542406A IL175424A0 IL 175424 A0 IL175424 A0 IL 175424A0 IL 175424 A IL175424 A IL 175424A IL 17542406 A IL17542406 A IL 17542406A IL 175424 A0 IL175424 A0 IL 175424A0
Authority
IL
Israel
Prior art keywords
quinolinecarbonitriles
cml
anilino
treatment
myelogenous leukemia
Prior art date
Application number
IL175424A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL175424(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL175424A0 publication Critical patent/IL175424A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL175424A 2003-11-06 2006-05-04 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) IL175424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (1)

Publication Number Publication Date
IL175424A0 true IL175424A0 (en) 2008-04-13

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175424A IL175424A0 (en) 2003-11-06 2006-05-04 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Country Status (18)

Country Link
US (2) US7417148B2 (xx)
EP (1) EP1680119A1 (xx)
JP (1) JP2007533655A (xx)
KR (1) KR20060118461A (xx)
CN (1) CN1874776A (xx)
AU (1) AU2004289243B2 (xx)
BR (1) BRPI0416289A (xx)
CA (1) CA2543163A1 (xx)
CO (1) CO5690608A2 (xx)
CR (1) CR8350A (xx)
EC (1) ECSP066548A (xx)
IL (1) IL175424A0 (xx)
MX (1) MXPA06004744A (xx)
NO (1) NO20062255L (xx)
RU (1) RU2006113691A (xx)
SG (1) SG146681A1 (xx)
WO (1) WO2005046693A1 (xx)
ZA (1) ZA200603596B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
SI1896020T1 (sl) 2005-06-17 2014-11-28 The Board Of Regents Of The University Of Texas System SKI 606 kot inhibitor src kinaze za zdravljenje osteolitičnih lezij
RU2007143434A (ru) * 2005-06-24 2009-07-27 Вайет (Us) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
TW200908982A (en) * 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
ECSP066548A (es) 2006-10-17
MXPA06004744A (es) 2006-07-05
US20050101780A1 (en) 2005-05-12
CA2543163A1 (en) 2005-05-26
SG146681A1 (en) 2008-10-30
EP1680119A1 (en) 2006-07-19
CO5690608A2 (es) 2006-10-31
ZA200603596B (en) 2009-12-30
NO20062255L (no) 2006-08-01
US7417148B2 (en) 2008-08-26
JP2007533655A (ja) 2007-11-22
BRPI0416289A (pt) 2007-01-23
KR20060118461A (ko) 2006-11-23
AU2004289243B2 (en) 2010-07-22
US20100029677A1 (en) 2010-02-04
AU2004289243A1 (en) 2005-05-26
WO2005046693A1 (en) 2005-05-26
CN1874776A (zh) 2006-12-06
CR8350A (es) 2006-10-06
US7919625B2 (en) 2011-04-05
RU2006113691A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
ZA200603596B (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
EP1689485A4 (en) CARDIOELECTROMAGNETIC TREATMENT
EP1638508A4 (en) SHUNT FOR GLUCKOM TREATMENT
EP1749827A4 (en) ANTITUMOR AGENTS
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
EP1599196A4 (en) ANTICANCER THERAPY
GB0326486D0 (en) Combination treatment
GB0312407D0 (en) Treatment
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
EP1536719A4 (en) TABLE
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
EP1952811A4 (en) USE OF ERIOCALYXIN B FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA
GB2405789B (en) Patient table
IL175689A0 (en) Enoxaparin for the treatment of cancer
AU2003291245A8 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
AP2956A (en) Parasiticidal composition
AU154258S (en) Game table
PT1590046T (pt) Composição para o tratamento de hiv ou sida
EP1365033A4 (en) MOLECULAR DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA
AU154608S (en) Game table
AU154131S (en) Table
GB0313630D0 (en) Compositions for the enhanced treatment of depression
GB0316502D0 (en) The structure of exotic panties
GB0327493D0 (en) Treatment medicament
EP1685846A4 (en) ANTITUMOR AGENT